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In-stent Restenosis after Carotid Angioplasty and Stenting: Post-
Carotid Endarterectomy Lesions Fare Equally as Well as True De Novo
Lesions
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Shah1, Jean M Panneton1. 1Division of Vascular Surgery, Eastern Virginia
Medical School, Norfolk, VA; 2Department of General Surgery, Eastern
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Objectives: Restenosis following carotid endarterectomy (CEA) can
be treated with carotid angioplasty and stenting (CAS), but concerns about
durability exist. Data for CAS restenosis following CEA is limited and
conflicting and includes arteries that have been radiated. The disease process
of radiated arterial restenosis is different. We compare the long-term results
of CAS performed after ipsilateral CEA to results of CAS for true de novo
carotid stenosis.
Methods: 269 consecutive CAS procedures between January 2003 and
August 2008 were performed on 254 patients. 18 patients were excluded for
neck radiation therapy to represent true de novo lesions for comparison.
Seventy four procedures were performed for post-CEA indication and 173
procedures for de novo lesions. Standard statistical analysis was used. In-
stent restenosis was defined as  50% stenosis using duplex ultrasound
internal carotid artery peak systolic velocity 220 centimeters per second
(cm/s) and internal to common carotid artery peak systolic velocity ratio
2.7.
Results:Mean age was 73 years (range: 43.7-90.4). 55%weremale and
45% female. Caucasians comprised 90% and African-Americans 8%. Mean
follow-up was 13.1 months (range, 0-63.4). Demographic information and
risk factors were similar except for age (73.8 years de novo versus 71.1 years
post-CEA; p0.035), smoking (62% post-CEA versus 42% de novo;
p0.004), symptomatic (27% post-CEA versus 45% de novo; p0.008),
and embolic protection use (92% post-CEA versus 99% de novo; p0.001).
Overall, 30-day risk of stroke was 3.2%, death was 1.2%, and myocardial
infarction was 0.8% with no group differences (p0.273, p0.53, and
p0.16, respectively. Three year overall survival was not significant: de novo
group at 75% compared to 53% for post-CEA group (p0.074). At four years
the overall freedom from stroke was 96% with no group difference (p0.19).
Primary patency at three years was similar, 89% for post-CEA and 91% for the de
novo group (p0.211).Only 3 patients (pNS) had duplex ultrasound criteria
indicative of80% stenosis, none required reintervention.
Conclusion: There is not an increased rate of in-stent restenosis
following CAS for post-CEA restenosis compared to non-radiated true de
novo lesions.
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Objective: Carotid angioplasty and stenting (CAS) is an increasingly
performed alternative to carotid endarterectomy. Complications include
hypoperfusion of the brain as a result of overstimulation of the barorecep-
tors, by balloon dilatation or by the radial force of the stent. In this study we
tested the radial force of four different carotid stents. Two open cell nitinol
stents (Acculink® and Protégé®), one hybrid nitinol stent (Cristallo Ideale®)
and a braided elgiloy stent (Wallstent®).
Methods: Five stents of each type were deployed in three loops of
bopet film. These films were attached to aluminium rods with copper strain
gauges, forming a half Wheatstone bridge. The radial force of the stent leads
to pulling of the rods and voltage differences in the strain gauges which can
be precisely and reliably measured. We performed two tests, one of stent
deployment and one simulation of a clinically relevant stenosis.
Results: In stent deployment, the Protégé® produced a peak radial
force of 62cN, the Wallstent® 38cN, the Acculink® 35cN and the Cristallo
Ideale® 15cN (p0,05). In the simulated stenosis (figure 1) the Protégé®
had the greatest peak radial force of 328cN and theWallstent® produced the
lowest radial force of 84 cN (p0,05).
Conclusions: Radial forces exerted by carotid stents vary significantly
between various stent designs. In both tests the Protégé® stent generates a
radial force far greater than all the other stents. Clinical results of CAS may
be very dependent of the specific stent used and may therefor not be
generalized for all carotid stent systems.In our opinion, besides flexibility
and free cell area, an objective comparison of radial force is necessary for a
well-considered choice of stent type in the individual patient.Author Disclosures: M.T. Voûte, None; J.M. Hendriks, None; J.H.H.
Van Laanen, None; P.M.T. Pattynama, None; B.E. Muhs, None;
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Introduction: Trials on CAS, typically in high risk patients, suggest a
1% higher stroke rate but show equivalency to CEA. Unfortunately, the
CEA results usually exceed the accepted limits of proven benefit set in ACAS
andNACET. To assess benefit at one institution, patients were prospectively
offered their choice of CAS or CEA, regardless of risk status.
Methods: Between October 2002 and May 2007, with IRB approval,
consecutive patients at a VA hospital were analyzed after they selected either
CAS or CEA. They were informed of a possible 1% greater risk of stroke with
CAS. A single Neurologist (JG) verified neurological exams. Variables
compared: age, beta-blocker use, diabetes (DM), hypertension (HTN),
coronary artery disease (CAD), respiratory disease (RD), intermittent clau-
dication (IC), stroke, TIA, amaurosis fugax, operative room time, transfu-
sion, length of stay (LOS), myocardial infarction, nerve injury, hematoma,
stroke and death. Statistical analysis was performed using Fischer’s Exact and
Mann-Whitney Tests.
Results: 92 patients underwent 98 procedures (48 CEA /50 CAS).
Although 75% were high risk, there were no differences in high/low risk,
asymptomatic/symptomatic patient choice of CAS vs. CEA, nor between:
age, HTN, DM, CAD, IC. The CEA group had a higher incidence of RD
(p0.015), TIA (P0.008) and smoking (P0.002). Operative time was
higher in CEA vs. CAS (2.1 hr. vs. 1.3 hr; P0.02). There was no difference
in LOS or transfusion. CEA had higher major complications: MI (2 vs. 0%),
nerve injury (4 vs. 0%) and hematoma (11 vs. 3%) compared to CAS
(p0.01). The 30 day stroke/mortality rates were no different: 0/2% and
2.1/0 % for CEA and CAS, respectively. Mean follow-up was 27.2 vs. 22.8
months for CEA vs. CAS, respectively with no late neurological symptoms
and similar deaths. One restenosis in each group was treated with CAS. Four
patients had contra lateral treatments (3 CEA underwent CAS and 1 CAS
underwent CEA).
Conclusion: When both surgical and endovascular treatment out-
comes are within established standards, pre-operative risk status need not be
the factor for recommending CAS. Consideration should be given to
in-dividual and /or institutional perioperative outcomes to guide reimburse-
ment recommendations to allow the patient a choice between CEA and
CAS.
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